PLASMA PHENYLETHYLAMINE IN SCHIZOPHRENIC-PATIENTS
PLASMA PHENYLETHYLAMINE IN SCHIZOPHRENIC-PATIENTS
复制标题
DOI：
10.1016/0006-3223(91)90168-l
复制
发表时间：
1991-07-15
影响因子：
10.6
通讯作者：
BOULTON, AA
中科院分区：
文献类型：
--
作者：
OREILLY, R;DAVIS, BA;BOULTON, AA
从41名符合DSM-III精神分裂症标准的患者和34名健康对照者中收集血浆样本。使用气相色谱-质谱负化学电离法测定苯乙胺（PE）水平。与对照组相比，精神分裂症患者的PE显着较高。偏执型和非偏执型患者的PE无差异。血浆PE似乎不受精神分裂症症状的严重程度（由BPRS，SANS和SAPS评定）或在测试的24小时内摄入的膳食苯丙氨酸量的影响。血浆PE与当前或过去暴露于精神抑制药物无关。然而，不可能在服用和不服用药物的两个时期对个体患者进行测试。因此，神经抑制剂暴露可能混淆了结果。这项研究提供了进一步的证据，PE过量可能在精神分裂症的病因学中发挥作用，但不支持以前的研究表明，这种异常仅限于偏执亚组。
Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic patients compared with controls. There were no differences in PE between paranoid and nonparanoid patients. Plasma PE did not appear to be influenced by the severity of schizophrenic symptoms (rated by BPRS, SANS, and SAPS) or by the amount of dietary phenylalanine ingested within 24 hr of testing. Plasma PE did not correlate with current or past exposure to neuroleptic medication. It was not possible, however, to test individual patients during two periods when they were taking and not taking medication. Thus it is possible that neuroleptic exposure may have confounded the results. This study provides further evidence that PE excess may play a role in the etiology of schizophrenia but does not support previous studies which suggest that such an abnormality is limited to the paranoid subgroup.